FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

StatusNot Yet Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2021 to Feb 5, 2030
    • Start date: Dec 2020 to Oct 15, 2028
    • Study completion date: Jun 2022 to Dec 15, 2030
    • Study site revised
    v14
  2. Re-verified, no change to tracked fieldsv13
  3. Primary completion date: Dec 15, 2020 to Dec 2021
    • Start date: Dec 1, 2019 to Dec 2020
    • Study completion date: Jun 2021 to Jun 2022
    v12
  4. Primary completion date: Dec 15, 2019 to Dec 15, 2020v11 Show 4 more changesShow less
    • Start date: Dec 1, 2018 to Dec 1, 2019
    • Primary endpoints: 1 to 2
    • Study completion date: Jun 2020 to Jun 2021
    • Secondary endpoints expanded, about 22 words
  5. Start date: Jun 1, 2019 to Dec 1, 2018v10
Show 8 earlier versionsHide 8 earlier versions
  1. Study site revisedv9
  2. Phase: Phase 1 to Phase 1/2v8 Show 6 more changesShow less
    • Primary completion date: Dec 2014 to Dec 15, 2019
    • Start date: Dec 2014 to Jun 1, 2019
    • Study completion date: Dec 2014 to Jun 2020
    • Interventions: FGF-1 (Drug) to FGF-1 (Drug), Placebo (Drug)
    • Study site revised
    • Study arms: 1 to 2
  3. Re-verified, no change to tracked fieldsv7
  4. Start date: Dec 2013 to Dec 2014v6
  5. Primary completion date: Jul 2013 to Dec 2014
    • Start date: Jan 2012 to Dec 2013
    • Study completion date: Dec 2013 to Dec 2014
    v5
  6. Start date: Jan 2008 to Jan 2012v4 Show 6 more changesShow less
    • Primary endpoints: 2 to 1
    • Primary completion date: Jul 2013
    • Study completion date: Dec 2013
    • Eligibility criteria expanded, about 294 words
    • Study arms: 0 to 1
    • Secondary endpoints shortened, about 2 words
  7. Start date: Aug 2007 to Jan 2008v3
  8. Start date: Jun 2007 to Aug 2007
    • Eligibility criteria expanded, about 224 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.
Trial Details
NCT Number NCT00424866
Lead Sponsor Venturis Therapeutics, Inc.
Conditions
(from sponsor)		 Peripheral Arterial Disease, Stenosis, Intermittent Claudication
Related terms Constriction, Pathologic, Intermittent Claudication, Ischemia, Peripheral Arterial Disease
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov